Status: Recruiting
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).
Participants needed: 85
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: OrphAI TherapeuticsUpdated: Jul 13, 2026Locations: 3
Eligibility criteria
Age 18-80 years (>70 y/o requires medical monitor approval) [+21]
Clinical and/or radiologic evidence of moderate to severe emphysema [+31]